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Abstract: Anaplastic thyroid cancer (ATC) is an undifferentiated and advanced form of thyroid cancer,
accompanied with a high ratio of epigenetic adjustment, which occurs more than genetic mutations.
In this study, we aimed to evaluate the synergistic anticancer effect (in vitro and in vivo) of the new
combination of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA) and sorafenib with radiation
therapy in pre-clinical models of ATC. The ATC cell lines, YUMC-A1 and YUMC-A2, were isolated
from the current patients who were treated with HNHA and sorafenib, either as monotherapy or
combination therapy. Synergistic anticancer effect of the combination therapy on the intracellular
signaling pathways and cell cycle was assessed via flow cytometry and immunoblot analysis. To
examine tumor shrinkage activity in vivo, an ATC cell line-derived mouse xenograft model was used.
Results showed that the combination therapy of HNHA and sorafenib with radiation promoted
tumor suppression via caspase cleavage and cell cycle arrest in patient-derived ATC. In addition, the
combination therapy of HNHA and sorafenib with radiation was more effective against ATC than
therapy with HNHA or sorafenib with radiation. Thus, the combination of HNHA and sorafenib
with radiation may be used as a novel curative approach for the treatment of ATC.
Keywords: patient-derived anaplastic thyroid cancer; N-hydroxy-7-(2-naphthylthio) heptanomide;
sorafenib; radiation therapy; apoptosis
1. Introduction
The thyroid gland secretes thyroid hormones that play decisive roles in managing
normal metabolism [1–3]. Thyroid cancer is classified into four main types, as follows:
anaplastic, papillary, follicular, and medullary [4,5]. Thyroid cancer is also categorized as
either well-differentiated or poorly differentiated/anaplastic, based on the characteristics of
cell differentiation and maintenance of the follicular cell phenotype. Differentiated thyroid
cancer is the most common type of thyroid cancer, accounting for more than 80%–90% of
all thyroid cancers and comprises papillary and follicular histological subtypes [6,7]. In
contrast, the incidence of poorly differentiated or anaplastic thyroid cancer (ATC) is just
2–3% of clinically recognized thyroid cancer cases. However, ATC has a poor prognosis and
demonstrates chemo-therapeutic resistance and aggressiveness [8], and the median overall
survival (OS) is limited to few months [9–11]. Most of the patients with ATC are elderly
and require effective treatment to control the swiftly growing tumor mass. Moreover,
nearly 50% of patients require pain medication due to distant metastases [12–14]. In most
of the patients, complete surgical resection is not feasible. As with this study, studies based
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on patient-derived ATC cell lines indicate promise that new clinical approaches to the
management of ATC will be found in the future. Recent studies have identified various
molecules and mechanisms that are precisely associated with the poor clinical results in
ATC [15,16]. Among these mechanisms, the synergistic anticancer effect of the histone
deacetylase (HDAC) inhibitor or sorafenib and radiation-induced suppression of advanced
cancer has been considered one of the probable reasons for poor clinical results [17–19].
The positive efficacy results obtained with HDAC inhibitors as anticancer agents resulted
in the approval of HDAC inhibitors by the US Food and Drug Administration (USFDA) for
the treatment of some cancer subtypes [20,21]. Several HDAC inhibitors are presently used
clinically as therapeutic drugs, either agents alone or combination with other anticancer
agents [19,22,23]. N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA) is an unusual
HDAC inhibitor that has been proved to have significantly higher anticancer activity than
trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA) [24–26]. In addition,
the USFDA recently authorized the use of sorafenib for ATC treatment [27]. Sorafenib
is a multi-kinase inhibitor that interrupts diverse signaling pathways, including platelet-
derived growth factor receptors (PDGFRs), vascular endothelial growth factor receptor
(VEGFR), and Raf kinases [28]. Additionally, sorafenib has also been approved for the
treatment of advanced renal cell carcinoma (RCC) and other human cancers [29–32].
In this study, we aimed to investigate a new clinical approach, the efficacy of the
combination therapy of HNHA and sorafenib with radiation in ATC cell lines and in vivo
mouse models of ATC.
2. Results
2.1. Patient Disease Characteristics
Patient demographics and disease characteristics are presented in Figure 1A. The
mean age of the patients was 63.6 years, and 60.9% of patients were females. Stage IVB
ATC and stage IVC ATC were diagnosed in 26.1 and 73.9% of the patients, respectively,
and 45.7% of patients underwent surgery, while 30.5% underwent complete resection. All
patients received chemotherapy with paclitaxel, and three patients previously received
adriamycin at another medical institution, and 93.5% of patients received radiation therapy.
The median OS for the 46 patients with ATC was 228 days (rage 58–1418) (Figure 1A).
Survival rate was 63.2% at 6 months and 23.9% at 1 year (Figure 1B). For this reason, we
researched more highly in differentiated than undifferentiated, ATC.




Figure 1. Information of ATC patients: (A) Patient characteristics and clinical features; (B) Survival 
rates of patients with anaplastic thyroid cancer. The cancer stage was determined according to the 
8th edition of the AJCC/UICC by the American Joint Committee on Cancer and the International 
Union Against Cancer. 
2.2. Characteristics of Patient-Derived Thyroid Cancer Cell Lines 
Various subtypes of patient-derived differentiated and undifferentiated thyroid can-
cer cell lines were acquired from the patient specimens (Figure 2A). YUMC-A1 (first iso-
lated patient-derived ATC) and YUMC-A2 (second isolated patient-derived ATC) were 
obtained from patients with ATC treated at the Severance Hospital, Yonsei University 
College of Medicine, Seoul, Korea. Therapy failure, cancer recurrence, and metastasis 
were reported in these patients. The results of the next-generation RNA sequencing to 
identify a series of differentially expressed genes (DEGs) showed that YUMC-A1 and 
YUMC-A2, patient-derived ATC (undifferentiated) cells, were associated with signifi-
cantly increased levels of cancer stemness (CD44high/CD24low, CDH2, KRAS CDC42, RAC1, 
MCPH1, SRGAP2, SRGAP2C, TWIST1, TWIST2, PROM1, ICAM1) and metastatic markers 
(BRACA1/2, KRT5, CD44, WNT4/16, ALDH1A1, CD29, SALL4) when compared with pa-
tient-derived differentiated thyroid cancer cells, YUMC-F1 (first isolated patient-derived 
follicular thyroid cancer), YUMC-M1 (first isolated patient-derived medullary thyroid 
cancer), and YUMC-P1 (first isolated patient-derived papillary thyroid cancer), as shown 
in Figure 2B,C. In ATC, the most significantly upregulated genes were BRACA2, CD44, 
CDC42, and RAC1. The top four upregulated and downregulated DEGs are shown in Fig-
ure 2C. Taken together, we concluded that study of the ATC could be of great value to 
therapeutic trials in the management of patients with stemness and metastatic cancer, in-
cluding drug-resistant properties. 
Figure 1. Information of ATC patients: (A) Patient characteristic and clinical features; (B) Survival rates of patients with
anaplastic thyroid cancer. Th cancer stage as determined acco d ng to the 8th dition of the AJCC/UICC by the Ame ican
Joint Committee on Cancer an the International Union Against Cancer.
2.2. Characteristics of Patient-Derived Thyroid Cancer Cell Lines
Various subtypes of patient-derived differe tiated and undifferentiated thyroid cancer
cell lines were acquired from the patient specimens (Figure 2A). YUMC-A1 (first isolated
patient-derived ATC) and YUMC-A2 (second isolated patient-derived ATC) were obtained
from patients with ATC treated at the Severance Hospital, Yonsei University College of
Medicine, Seoul, Korea. Therapy failure, cancer recurrence, and metastasis were reported
in these patients. The results of the next-generation RNA sequencing to identify a series
of differentially expressed genes (DEGs) showed that YUMC-A1 and YUMC-A2, patient-
derived ATC (undifferentiated) cells, were associated with significantly increased levels
of cancer stemness (CD44high/CD24low, CDH2, KRAS CDC42, RAC1, MCPH1, SRGAP2,
SRGAP2C, TWIST1, TWIST2, PROM1, ICAM1) and metastatic markers (BRACA1/2, KRT5,
CD44, WNT4/16, ALDH1A1, CD29, SALL4) when compared with patient-derived differenti-
ated thyroid cancer cells, YUMC-F1 (first isolated patient-derived follicular thyroid cancer),
YUMC-M1 (first isolated patient-derived medullary thyroid cancer), and YUMC-P1 (first
isolated patient-d rived papillary thyroid cancer), as shown in Figure 2B,C. In ATC, the
most significantly upregulated genes were BRACA2, CD44, CDC42, and RAC1. The top four
upregulated and downregulated DEGs are shown in Figure 2C. Taken together, we con-
cluded that study of the ATC could be of great value to therapeutic trials in the management
of patients with stemness and metastatic cancer, including drug-resistant properties.




Figure 2. Characteristics of all thyroid cancer cell lines examined: (A) Characteristics of patient-
derived subtypes of thyroid cancer cell lines, including viability after drug treatment of all thyroid 
cancer cell lines examined; (B) Hierarchical clustering of annotated genes revealed distinct gene 
expression. Gene expression profiles of various subtypes of patient-derived thyroid cancer cells; 
(C) The top four upregulated and downregulated differentially expressed genes (DEGs) for vari-
ous subtypes of thyroid cancer cells. 
2.3. Combination of HNHA and Sorafenib with Radiation Was More Effective Than Either 
HNHA or Sorafenib with Radiation 
To evaluate the synergistic anticancer effects of the combination of HNHA and so-
rafenib on patient-derived ATC cells, we tested the proliferation of YUMC-A1 and 
YUMC-A2 cells in the presence of both the compounds, either in combination or alone, 
along with radiation. A combination of HNHA, sorafenib, and radiation was inhibited cell 
proliferation more effectively than either agent alone with radiation (Figure 3A,C), in a 
dose-dependent type (Figure 3B,D). Furthermore, the combination of HNHA, sorafenib, 
and radiation had a lower half maximal inhibitory concentration (IC50) than that of HNHA 
or sorafenib with radiation therapy in YUMC-A1 and YUMC-A2 cells (Table 1). These 
results show that this polypharmacy may offer a novel clinical approach for targeting 
stemness, metastatic cancer, including drug-resistant ATC, with low dosage of anticancer 
drugs. 
Figure 2. Characteristics of all thyroid cancer cell lines examined: (A) Characteristics of patient-derived subtypes of thyroid
cancer cell lines, including viability after drug treatment of all thyroid cancer cell lines examined; (B) Hierarchical clustering
of annotated genes revealed distinct gene expression. Gene expression profiles of various subtypes of patient-derived
thyroid cancer cells; (C) The top four upregulated and downregulated differentially expressed genes (DEGs) for various
subtypes of thyroid cancer cells.
2.3. Combination of HNHA and Sorafenib with Radiation Was More Effective Than Either HNHA
or Sorafenib with Radiation
To evaluate the synergistic anticancer effects of the combination of HNHA and so-
rafenib on patient-derived ATC cells, we tested the proliferation of YUMC-A1 and YUMC-
A2 cells in the presence of both the compounds, either in combination or alone, along
with radiation. A combination of HNHA, sorafenib, and radiation was inhibited cell
proliferation more effectively than either agent alone with radiation (Figure 3A,C), in a
dose-dependent type (Figure 3B,D). Furthermore, the combination of HNHA, sorafenib,
and radiation had a lower half maximal inhibitory concentration (IC50) than that of HNHA
or sorafenib with radiation therapy in YUMC-A1 and YUMC-A2 cells (Table 1). These
results show that this polypharmacy may offer a novel clinical approach for targeting stem-
ness, metastatic cancer, including drug-resistant ATC, with low dosage of anticancer drugs.




Figure 3. Synergistic anticancer effect of HNHA, sorafenib, and radiation on patient-derived thy-
roid cancer cells compared with the effects of each agent alone with radiation. Cell viability and 
proliferation assay of HNHA and sorafenib combined, each agent alone, or HNHA and sorafenib 
combined with radiation on patient-derived ATC cell lines. YUMC-A1 and YUMC-A2: (A,B) 
YUMC-A1 and (C,D) YUMC-A2,. Points indicate mean percentage of the value observed in the 
solvent-treated control. All experiments were repeated at least three times. Data represent means ± 
SD. * p < 0.05, ** p < 0.01, and *** p < 0.005 vs. control. 
Table 1. IC50 values for the combination of HNHA, sorafenib, and radiation therapy (RT) in 
YUMC-A1 and YUMC-A2 cells. Each data point signifies the mean of three independent MTT 
assays, performed in triplicate. SEM, standard error of the mean. MTT, 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide. * is lowest half maximal inhibitory concentration. 
Cell Line Hisopathology Animal Cell Proliferation IC50 (μM) 




enib + RT 
YUMC-A1 Thryoid, anaplastic Human 16.19 (±0.6) 10.17 (±0.6) 6.71 (±0.1) 7.12 (±0.9) 2.74 (±0.6) * 
YUMC-A2 Thyroid, anaplastic Human 18.16 (±0.4) 12.14 (±0.5) 8.14 (±1.3) 10.33 (±0.7) 4.08 (±0.2) * 
2.4. Combination of HNHA and Sorafenib with Radiation Was More Effective in Inducing 
Apoptosis and Cell Cycle Arrest in YUMC-A1 and YUMC-A2 Than HNHA or Sorafenib with 
Radiation 
Next, we investigated the mechanism of the synergistic anticancer effects of the com-
bination of HNHA, sorafenib, and radiation on YUMC-A1 and YUMC-A2 cell lines. We 
estimated the levels of expression of the markers of cell cycle (cyclin D1 and p21), ER stress 
(GRP 78 and CHOP), and apoptotic signaling pathways (Bcl 2 and cleaved caspase 3) on 
YUMC-A1 and YUMC-A2 by flow cytometry, immunoblot (whole cell lysate or cellular 
Figure 3. Synergistic anticancer effect of HNHA, sorafenib, and radiation on patient-derived thyroid cancer cells compared
with the effects of each agent alone with radiation. Cell viability and proliferation assay of HNHA and sorafenib combined,
each agent alone, or HNHA and sorafenib combined with radiatio on patie t-d rived ATC cell lines. YUMC-A1 and
YUMC-A2: (A,B) YUMC-A1 and (C,D) YUMC-A2,. P ints indicat m an percentage of the value observed in the solvent-
treated control. All experiments were repeated at least three times. Data represent means ± SD. * p < 0.05, ** p < 0.01, and
*** p < 0.005 vs. control.
Table 1. IC50 values for the combination of HNHA, sorafenib, and radiation therapy (RT) in YUMC-A1 and YUMC-A2 cells.
Each data point signifies the mean of three independent MTT assays, performed in triplicate. SEM, standard error of the
mean. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. * is lowest half maximal inhibitory concentration.
Cell Line Hisopathology Animal
Cell Proliferation IC50 (µM)
HNHA Sorafenib HNHA + RT Sorafenib +RT
HNHA +
Sorafenib + RT
YUMC-A1 Thryoid,anaplastic Human 16.19 (±0.6) 10.17 (±0.6) 6.71 (±0.1) 7.12 (±0.9) 2.74 (±0.6) *
Y - 2 Thyroid,anaplastic Human 18.16 (±0.4) 12.14 (±0.5) 8.14 (±1.3) 10.33 (±0.7) ( ) *
2.4. Combination of HNH and Sorafenib with Radiation Was More Effective in Inducing
Apoptosis and Cell Cycle Arrest in YUMC-A1 and YUMC-A2 Than HNHA or Sorafenib
with Radiation
Next, we investigated the mechanism of the synergistic anticancer effects of the
combination of HNHA, sorafenib, and radiation on YUMC-A1 and YUMC-A2 cell lines.
We estimated the levels of expression of the markers of cell cycle (cyclin D1 and p21), ER
stress (GRP 78 and CHOP), and apoptotic signaling pathways (Bcl 2 and cleaved caspase
3) on YUMC-A1 and YUMC-A2 by flow cytometry, immunoblot (whole cell lysate or
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cellular fractionation), and immunofluorescence analyses. The combination of HNHA and
sorafenib with radiation significantly induced the sub-G0G1 population, resulting in the
induction of apoptosis and cell cycle arrest in YUMC-A1 and YUMC-A2 cells (Figure 4A,B)
and leading to ER stress-mediated apoptosis, cell cycle arrest, and strong inhibition of
YUMC-A1 and YUMC-A2 (Figure 4C,D). Immunoblot analysis of the protein expression
levels in YUMC-A1 and YUMC-A2 indicated that the combination of HNHA, sorafenib,
and radiation induced the most marked increase in the levels of p21, GRP 78, CHOP,
and cleaved caspase 3 (which are associated with cell cycle arrest and are ER stress and
proapoptosis markers). In contrast, the combination treatment resulted in decrease in the
levels of cyclin D1 and Bcl 2, which are positive regulators of cell cycle and anti-apoptotic,
compared with responses to HNHA or sorafenib administration with radiation.
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DNA damage is known to induce apoptosis by releasing cytochrome c from mito-
chondria [33]. To assess the mechanism of apoptosis induced by the combination of 
HNHA, sorafenib, and radiation, we evaluated the expression of cytochrome c and caspa-
ses with immunofluorescence and immunoblot analysis (Figure 5). Results from the im-
munofluorescence indicated that cytochrome c was located and accumulated in the nu-
clear, thus proposing that combination of HNHA, sorafenib, and radiation caused apop-
tosis via a cytochrome-c-dependent pathway in undifferentiated thyroid cancer cell lines, 
YUMC-A1 (Figure 5A,C) and YUMC-A2 (Figure 5B,D). Immunoblot analysis after subcel-
lular fractionation confirmed that cytochrome c was translocated into the nucleus after 
Figure 4. Cell cycle arrest and apoptosis analysis by quantitation of DNA content with propidium iodide and immunoblot
analysis: (A,B) Cell cycle arrest and apoptosis were significantly induced by th combination of HNHA, sorafenib, and
radiation in patient-derived ATC cell l es, YUMC-A1 and YUMC-A2. Cells were exposed to th indicat d inhibitors,
harvested, and stained with propidium iodide before analysis by flow cytometry and FlowJo v8; (C,D) Immunoblot
analysis of the markers of cell cycle, apoptosis, anti-apoptosis, and ER stress on patient-derived ATC cell lines, YUMC-A1
and YUMC-A2.
2.5. Combination of HNHA, Sorafenib, and Radiation Induced Cytochrome c Release from
Mitochondria and Translocation from the Cytoplasm to the Nucleus in ATC Cells
DNA damage is known to induce apoptosis by releasing cytochrome c from mitochon-
dria [33]. To assess the mechanism of apoptosis induced by the combination of HNHA,
sorafenib, and radi tion, we evaluated the expressi n of cyto hrome c and caspases with
immunofluorescence and mmunoblot an lysis (Figure 5). Results from th immunoflu-
orescence indicated that cytochrome c was located and accumulated in the nuclear, thus
proposing that ombination of HNHA, sorafenib, and radiation ca sed poptosis via a
cytochrome-c-dependent pathway in undifferentiated thyroid cancer cell lines, YUMC-A1
(Figure 5A,C) and YUMC-A2 (Figure 5B,D). Immunoblot analysis after subcellular frac-
tionation confirm d that cytochrome c was translocated into the nucleus after combination
Int. J. Mol. Sci. 2021, 22, 536 7 of 16
treatment with HNHA, sorafenib and radiation (Figure 5C,D). In summary, these results
suggest the combination of HNHA, sorafenib, and radiation induces apoptosis via caspase-
and cytochrome-c-dependent pathways in undifferentiated thyroid cancer cells.
Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 7 of 16 
 
 
combination treatment with HNHA, sorafenib and radiation (Figure 5C,D). In summary, 
th se results suggest the combination of HNHA, soraf nib, and radiation induces apop-
tosis via caspase- a d cyt chrome-c-dependent pathways i  undifferentia ed thyroid c n-
cer cells. 
 
Figure 5. Synergistic anticancer effect of HNHA, sorafenib, and radiation was most induced nu-
clear-translocatyion of the cytochrome c on patient-derived ATC cell lines. Immunofluorescence 
(A,B) examined at ×400 magnification; scale bar, 20 μm and subcellular fractionation (C,D) analy-
sis. Cytochrome c was most translocated and accumulated in the nucleus by HNHA, sorafenib, 
and radiation treatment group on patient-derived ATC cell lines: (A,C) YUMC-A1 and (B,D) 
YUMC-A2. 
2.6. Combination of HNHA, Sorafenib, and Radiation Significantly Suppressed Tumor Growth 
in a Mouse Xenograft Model 
To estimate the synergistic in vivo anticancer efficacy of the combination of HNHA, 
sorafenib, and radiation, we developed a mouse xenograft model with YUMC-A1 and 
YUMC-A2, patient-derived ATC cell lines (Figure 6). Results showed that HNHA or so-
rafenib treatment with radiation marginally suppressed YUMC-A1 and A2 cell xenograft 
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of mice treated with HNHA or sorafenib administration with radiation (Figure 6C,D). 
There was no evidence of systemic toxicity and mortality in any group. Change in body 
weight was not significantly different among the two groups (Figure 6E,F). As anti-apop-
totic activity is crucial for the appraisal of oncogenesis and Bcl-2 serves as a critical marker 
of anti-apoptotic activity, we confirmed this marker by immunohistochemistry analysis 
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Figure 5. Synergistic anticancer effect of HNHA, sorafenib, and radiation was most nduced nuclear-tr nsloca yion of the
cytochrome c on patient-derived ATC ell lines. Immun flu rescence (A,B) examined at ×400 magnification; scale bar,
20 µm and subcellular fractionation (C,D) analysis. Cytochrome c was most translocated and accumulated in the nucleus by
HNHA, sorafenib, and radiation treatment group on patient-derived ATC cell lines: (A,C) YUMC-A1 and (B,D) YUMC-A2.
2.6. Combination of HNHA, Sorafenib, and Radiation Significantly Suppressed Tumor Growth in a
Mouse Xenograft Model
To estimate the synergistic in vivo anticancer efficacy of the combination of HNHA,
sorafenib, and radiation, we developed a mouse xenograft model with YUMC-A1 and
YUMC-A2, patient-derived ATC cell li es (Figure 7). Results showed that HNHA or
sorafenib treatment with radiation marginally suppr ssed YUMC-A1 and A2 cell xenograft
tumors, whereas the combination of HNHA, sorafenib, and radiation significantly induced
tumor shrinkage (Figure 7A,B). Moreover, mice in the HNHA, sorafenib, and radiation
combination treatm nt group had significantly m ller tumor volumes than those of mice
treated with HNHA or sorafenib administration w th radiation (Figure 7C,D). There was
no evidence of syst mic toxicity and mortality in any group. Change in body weight
was not significantly different among the two groups (Figure 7E,F). As anti-apoptotic
activity i crucial for the appraisal of oncoge esis and Bcl-2 serves as a critical marker of
anti-apoptotic activity, we confirmed this marker by immunohistochemistry alysis of
YUMC-A1 and YUMC-A2 cell xenograft tumors. Results indicated that the mice in the
HNHA, s rafenib, and radiation treatment group proved the maximum diminish in Bcl-2
expression among all the groups (Figure 7G,H). These results were supported that t e
combination of HNHA, sorafenib, and radiation showed potent anticancer effects in cancer
stem cells (CSCs) and undifferentiated cancer cell xenograft model.
Int. J. Mol. Sci. 2021, 22, 536 8 of 16
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cell xenografts (n = 10 mice/gr up). Data represent the mean tumor volumes. Co-treatment with HNHA and sorafenib
with radiation showed the maximum reduction in tumor weight of the dissected tumor weight in patient-derived ATC,
YUMC-A1 (C) and -A2 (D) cell xenografts. The compounds had no significant effect on body weight of patient-derived
ATC, YUMC-A1 (E) and -A2 (F) cell xenografted mice. (G,H) Immunohistochemical analysis of Bcl-2 proteins in tumor
tissues following the indicated treatments. Examined at ×400 magnification; scale bar, 80 µm. Each assay was performed
in triplicate and representative images are displayed. * p < 0.05, ** p < 0.01, and *** p < 0.005 vs. control. MetaMorph 4.6
image-analysis software was used to quantify the immunostained target protein.
Consequently, these results propose a promising new curative approach to treat
patients at a high risk of cancer-related mortality.
3. Discussion
The incidence of thyroid cancer is the highest among ordinary endocrine-related ma-
lignancies [34], and its worldwide occurrence is steadily increasing, including in Korea [35].
In 2011, the age-factual cancer occurrence ratio was 81.0 per 100,000, according to the data
curated in the Korea National Cancer Incidence Database. It has been reported that the
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occurrence of thyroid cancer increase steadily in both men and women, and it is the most
well-worn cancer among women in Korea since 2009 [36]. High-resolution ultrasonography
has served to early detection of asymptomatic small thyroid nodules [37] and resulted in a
reduction in the size ratio of identified thyroid cancers [38,39]. Many surgically removed
cases of thyroid cancer were mainly owing to expansion in cancers determined at 1 cm
or less. As a result, an increase in the assessment of thyroid cancer via neck ultrasonog-
raphy and treatment in the early phase have moderated thyroid cancer-related mortality.
However, ATC still remains one of the most common drug-resistant cancers [40]. Thyroid
cancer types can be classified into those originated from follicular cells (well-differentiated
follicular and papillary cancer), which frequently have a serendipitous diagnosis, or into
ATC. The latter is a clinically aggressive form of thyroid cancer with poor diagnosis and
includes poorly differentiated thyroid cancer [6,8,41]. ATC is considered a refractory cancer
subtype, owing to its drug resistance and aggressive behavior [8,14]. Studies have reported
that the median OS in patients with ATC is only several months [42,43].
Therefore, there is an urgent need to search for novel clinical approaches for the
treatment of ATC. In this study, we proposed a promising novel treatment strategy for
some intractable diseases in future. Synergistic anticancer effects of drugs that inhibit
non-overlapping cancer pathways are a reasonable approach to suppress cancer cell pro-
liferation. Furthermore, it is possible to reduce the doses of drugs when administered
in combination with radiation and thereby increase the therapeutic efficacy and reduce
the side effects. Epithelial–mesenchymal transition (EMT) is known to be connected to
therapeutic resistance and recurrence as well as the acquisition of stem cell like features and
is adequate to provide differentiated normal and cancer cells with stem cell features [44–47].
CSCs (including ATC) are poorly differentiated, have stem cell-like features [48], and have
the ability to evolve. Moreover, these cells are connected with metastasis and therapeutic
resistance [24]. Based on these findings related to CSCs, ATC was indicated to present
a high expression of markers of the EMT and fibroblast growth factor receptor (FGFR)
signaling pathway. In this study, based on the results of NGS (Next Generation Sequencing)
analysis, the ATC cell lines showed EMT-mediated drug resistance through the FGFR
signaling pathway and were a subtype of CSCs. Consequently, we concentrated on the
effect of inhibition of the ATC by composition of anticancer drug and HDAC inhibitor,
which would be promising therapeutic agent for the treatment of ATC cells in combination
with tyrosine kinase inhibitors (TKIs), including sorafenib. Sorafenib is a commonly used
multi-kinase inhibitor which inhibits the activity of Ser/Thr kinase Raf (which play a
significant role in tumor cell proliferation or signaling) and angiogenesis-related receptor
tyrosine kinases, VEGFR2 and PDGFR [28,49–52]. Sorafenib was recently approved for
the treatment of refractory thyroid cancer [53]. It has been reported that the HDAC in-
hibitors increase p21 expression in various cell types via promoter hyper-acetylation [54].
Decline in p21 expression has been shown to be influenced by the lethality of HDAC
inhibitors and DNA injury agents in varied cancer subtypes such as thyroid cancer, RCC,
and leukemia [26,55,56]. It has been suggested that p21 is cleaved by caspase-3 for DNA
damage-mediated apoptosis [57]. Furthermore, sorafenib-mediated transcriptionally in-
hibition could result in the down-regulation of p21 expression. Due to these reasons, it
could be interesting to research whether the sorafenib mediated down-regulation of p21
expression can origin the synergistic interaction between HNHA and sorafenib.
In this research, we indicated that the combination treatment of HNHA, sorafenib,
and radiation had a lower IC50 in ATC than that of either drug alone with radiation. The
mechanism radical to these synergistic anticancer effects of either agent on ATC cell lines
involved trigger of cell cycle arrest and apoptosis. However, the results from this study
should be interpreted taking into account the limitation that the cells were obtained from
a small number of patients. Nonetheless, this new combination of anticancer drugs and
radiation for effective suppression of the refractory cancer could have potential clinical
application and needs to be further evaluated.
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4. Materials and Methods
4.1. Study Design
This research was a retrospective, single-center analysis of patients with proved ATC
(diagnosed between February 2013 and November 2019). The electronic medical documents
of the available patients were reviewed to extract data on clinical characteristics, including
age, prior treatment, tumor characteristics and treatment outcomes. All process involving
patients were carried out in agreement with the ethical standards of institutional regulations
and all applicable local/national regulations, and with the 1964 Helsinki declaration and
its later amendments or comparable ethical standards. In agreement with the Bioethics
and Safety Act of Korea, formal consent was not requested for this type of retrospective,
observational analysis.
4.2. Patients
Patients with proved ATC who accepted the combination therapy were eligible for
inclusion in the analysis. Pathologic conformation of ATC was requested to confirm the
prognosis of ATC, either through surgery or through open biopsy or core needle biopsy.
Patients were followed up for at least 1 year or until death happened.
4.3. Tissue Specimens
Fresh tumors were collected from patients with histologically and biochemical proven
ATC who were treated at the Severance Hospital, Yonsei University College of Medicine,
Seoul, Korea. Fresh tumors were collected throughout surgical excision of ATC metastatic
and primary sites. For the purpose of this study, we chose one patient with advanced
metastatic ATC.
4.4. Ethical Considerations
The research protocol was approved by the Institutional Review Board of Severance
Hospital, Yonsei University College of Medicine (IRB Protocol: 3-2019-0281). Cell sam-
ples were acquired from patients at the Severance Hospital, Yonsei University College of
Medicine, Seoul, Korea.
4.5. Statistical Analysis
For the analysis of study results, categorical variables were described by proportion
and frequency, while summary statistics (range, median) were used to describe continuous
data. Survival curves were generated with the Kaplan–Meier method founded on the
log-rank test. As this was a retrospective analysis, no regular statistical comparisons were
carried out.
4.6. Tumor Cell Isolation and Primary Culture
After resection, tumors were kept in normal saline with antibiotic and antifungal
agents and transfered to the laboratory. Further protocol details are recounted in our
previous article [48].
4.7. Preparation of DNA
FFPE (Formalin-Fixed and Paraffin-Embedded) DNAs were isolated with the QIAamp
DNA FFPE Tissue Kit (Qiagen, Valencia, CA, USA), pursuant to the manufacturers’ instruc-
tions. Initial QC tests of FFPE DNA were carried out with electrophoresis on 1% agarose
gels and the Qubit dsDNA HS Assay Kit used the Qubit 2.0 fluorometer (Life Technologies,
Carlsbad, CA, USA), pursuant to the manufacturers’ manual.
4.8. Preparation of Libraries
Libraries were prepared used the SureSelect XT protocol (Agilent Technologies, Santa
Clara, CA, USA) used Custom Panel by the Macrogen (Macrogen, Seoul, Korea), and their
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quality was checked with the 2100 Bioanalyzer (Agilent). Further protocol details are
recounted in our previous article [58].
4.9. Analysis of DNA Sequences
The adapter sequences were eliminated by fastp (Chen, 2018). Trimmed reads were
aligned to the reference genome (GRCh37/hg19) with BWA-MEM (Li, 2013). Poorly
mapped reads that had mapping quality (MAPQ) below 20 were eliminated with Sam-
tools version 1.3.1 (Li et al., 2009). Duplicated reads were removed with Sambamba
markdup (version 0.6.7) (Tarasov, 2015). Base quality of deduplicated reads was recal-
ibrated with GATK BaseRecalibrator. Somatic mutations, including single nucleotide
variants (SNVs) and small insertions and deletions (INDELs), were identified with Mu-
Tect2 algorithm (Cibulskis et al., 2013) [59–61]. Further protocol details are recounted in
our previous article [62].
4.10. Cell Culture
Patient-derived ATC cells were acquired from the patient and grown in RPMI-1640
medium with 10% FBS (Authentication by short tandem repeat profiling/karyotyping/
isoenzyme analysis). Mycoplasma contamination was invariably tested used the Lookout
Mycoplasma PCR Detection Kit (MP0035, Sigma-Aldrich, MO, USA).
4.11. Cell Viability Assay
Cell proliferation was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetra-
zolium bromide (MTT) assay. Further protocol details are recounted in our previous article [62].
4.12. Irradiation
For in vitro tests, YUMC-A1 and YUMC-A2 cells were irradiated used Faxitron X-ray
machine (Faxitron Bioptics, Tucson, AZ, USA) at 3–5 Gray (Gy), followed by treatment
with HNHA or sorafenib alone and the combination of HNHA / sorafenib. For this
experiment, mice were treated with the Small Animal Radiation Research Platform (SARRP)
[High-resolution, small animal radiation study platform with x-ray tomographic guidance
capabilities [62]. The tumors were irradiated with a circular beam of 1cm diameter with
three successive daily fractions of 3 Gy.
4.13. Flow Cytometry Analysis of Cell Cycle
Cells were treated with HNHA and sorafenib alone or in combination with radiation
in RPMI-1640 medium including 10% FBS for 40 h, harvested by trypsinization, and fixed
in 70% ethanol. Further protocol details are recounted in our previous article [48].
4.14. Immunofluorescence Analysis and Confocal Imaging
The expression of cytochrome c was analyzed by immunofluorescence staining.
Primary antibody was used anti-cytochrome c (1:25; Abcam, Cambridge, UK) in 5%
bovine serum albumin in PBS. Further protocol details are recounted in our previous
article [62]. Images were acquired and analyzed a confocal microscope (LSM Meta 700;
Zeiss, Oberkochen, Germany) and Zeiss LSM Image Browser, version 4.2.0121.
4.15. Cellular Fractionation
Cellular fractions were arranged with the NEPER Nuclear and Cytoplasmic Extraction
kit (Thermo Scientific, 78833, Waltham, MA, USA) in conformity with the manufacturer’s
instructions. Further protocol details are recounted in our previous article [26].
4.16. Immunoblot Analysis
Primary antibodies against GRP 78 and CHOP bought from Cell Signaling Technology
(Danvers, MA, USA), p21, Bcl 2, cytochrome c, and histone H2B (bought from Abcam), and
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cyclin D1, caspase 3, and β-actin (bought from Santa Cruz Biotechnology, Santa Cruz, CA,
USA) overnight at 4 ◦C. Further protocol details are recounted in our previous article [62].
4.17. Human Thyroid Cancer Cell Xenograft
Patient-derived ATC cells (5.4 × 106 cells/mouse) were cultured in vitro and then
injected subcutaneously into the upper left flank region of female NOD/Shi-scid, IL-2Rγ
KOJic (NOG) mice. Further protocol details are recounted in our previous article [62]. All
experiments were confirmed by the Animal Experiment Committee of Yonsei University.
4.18. Immunohistochemistry
Primary monoclonal antibodies against Bcl 2 (Abcam), diluted with PBS (1:100),
overnight at 4 ◦C. All tissue sections were counterstained with hematoxylin, dehydrated,
and then mounted. Further protocol details are recounted in our previous article [62].
4.19. Statistical Analysis
Statistical analyses were carried out with GraphPad Prism software (GraphPad Soft-
ware, Inc., La Jolla, CA, USA). Immunohistochemistry results were subjected to one-way
analysis of variance, followed by a Bonferroni post hoc test. Values were indicated as
means ± SEM. p values < 0.05 were considered as statistically significant.
4.20. Image Analysis
The MetaMorph 4.6 software (Universal Imaging Co., Downingtown, PA, USA) was
used for computerized quantification of immunostained target proteins.
5. Conclusions
Synergistic anticancer activity of the HNHA, sorafenib, and radiation therapy was
more effective than treatment with HNHA or sorafenib alone with radiation in patient-
derived ATC. These findings can be useful to design future rational clinical studies in
patient with ATC to develop effective therapies.
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